The global regulatory map.

Article 315 of Mexico's General Health Law, modified November 2015. Requires all establishments to obtain a license and authorization from COFEPRIS to collect, conserve, analyze, prepare, supply, and dispose of organs, tissues, and cells.

Expanded allogeneic mesenchymal stem cell therapy administered in licensed hospitals by qualified physicians, with appropriate quality-control standards on the manufacturing lab. Direct local applications (joint, lumbar, cervical) under hospital-based oversight are permitted.

A facility must hold separate licenses for collection, processing/expansion, storage, and clinical application. Each license requires documentation of the facility, equipment, procedures, and physician training. Manufacturing standard: NOM-059-SSA1-2015, Mexico's Official Norm for GMP.

Mexico is among the top global destinations for medical tourism, welcoming over 1.2 million international patients annually. Tijuana, Mexico City, Cancún, Guadalajara, and Monterrey are the major corridors. Tijuana, where Celva operates, is the destination most accessible to U.S. West Coast patients.

Cell therapy in Panama operates under hospital-based oversight, with the lab and clinical operation typically licensed separately under MINSA. Similar in spirit to Mexico's model, with specific differences in licensing categories.

Stem Cell Institute Panama (SCI), founded 2007 by Neil Riordan, PhD. Affiliated with Medistem Panama (MPI) an 11,000 sq ft ISO 9001-certified lab in the City of Knowledge research park, with multiple certified cleanrooms and laminar flow hoods. Licensed by MINSA.

Expanded allogeneic MSC therapy, particularly cord-derived cells, under the hospital-based oversight model. Panama has been a recognized international destination for stem cell therapy since the late 2000s.

SCI/Medistem reports more than 50,000 procedures across 15+ years of operation. Self-reported figure, not independently audited.

Cell therapy in Cayman is structured differently from Mexico or Panama. Treatment is offered under U.S.-IRB-approved clinical study protocols, with the protocol registered with the Government of the Cayman Islands. The patient is enrolled in what is positioned as a patient-funded clinical study rather than receiving an approved commercial therapy.

DVC Stem in Grand Cayman, under IRB-approved study protocol HPC/CTR/003 "Evaluation of Cultured Expanded Allogeneic, Cord-Derived Mesenchymal Stem Cells, Deployed via Intravenous Injection for Safety and Effect on Systemic Inflammation."

DVC Stem's cells are manufactured in a U.S.-based partner laboratory FDA-registered, cGMP-compliant, ISO 9001 and ISO 13485 certified, AATB-certified tissue donors. Cells made under U.S. quality standards; administered in Cayman under the IRB study protocol.

Positioned as more conservative on the regulatory side cells made under U.S. cGMP, administered as part of an IRB-approved study rather than as approved commercial therapy. The trade-off: the patient is in a study framework, not a clinical-care framework.

EU Regulation 1394/2007 introduced the "Hospital Exemption" allowing EU member states to regulate non-routinely-manufactured ATMPs under their own national laws. Germany implemented this in July 2009. Section 4b of the German Drug Law specifies the pathway permitting certified clinics with a Hospital Exemption license to produce and administer cell-based products that are not routinely manufactured.

Cell therapy under PEI hospital-exemption licensing for autologous and certain allogeneic preparations under specific clinical conditions. More restrictive than Mexico or Panama, but permits some categories of treatment the U.S. FDA framework does not.

Germany's framework is genuinely enforced. The XCell-Center in Düsseldorf and Cologne was closed by PEI and regional authorities in April 2011, following enforcement action after the death of an 18-month-old patient from internal bleeding after intracranial stem cell injection.

The XCell case demonstrated that the German framework permits cell therapy under specific conditions but does not tolerate operators outside those conditions. A meaningful contrast to enforcement patterns elsewhere on this map.

Two laws enacted November 2014. The Act on the Safety of Regenerative Medicine (RM Act) covers clinical research and medical practice using processed cells. The Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act) introduces a specific regulatory framework for regenerative medicine products.

The PMD Act introduces conditional and time-limited marketing approval. After exploratory trials demonstrate probable benefit and proven safety, a product can receive conditional approval allowing immediate marketing and use. The sponsor must then continue to collect efficacy data for up to seven years to convert conditional approval to full approval.

Temcell HS Injection allogeneic MSC product for acute GvHD, the first allogeneic regenerative medicine product to receive full PMD Act approval (Sept 2015). HeartSheet skeletal myoblast sheet for severe heart failure; conditional approval later withdrawn after follow-up data did not confirm efficacy. STEMIRAC autologous bone-marrow MSC product for spinal cord injury; conditional approval on a small Phase 2 trial.

Japan's pathway is the most explicitly forward-leaning of the regulatory-purist alternatives. The conditional-approval framework was designed specifically to give patients earlier access to regenerative medicine products while continuing to collect efficacy data. The HeartSheet withdrawal demonstrates conditional approval is genuinely conditional.

Decree 2493 of 2004. Hematopoietic stem cell transplants may be performed only by authorized transplant centers using cells from INVIMA-licensed banks. Treatments with cultured or expanded MSC are not approved for routine clinical use; they may be offered only within INVIMA-authorized clinical trials with ethics committee oversight.

Multiple sources note that enforcement of Colombia's expanded-MSC restrictions has been inconsistent. Treatments are commonly offered commercially despite the technical requirement that they be administered only within INVIMA-approved trials. Patients evaluating Colombian clinics should verify that the specific clinic is operating under either an INVIMA-approved trial or appropriate licensing for what they're offering.

BioXcellerator in Medellín: Phoenix, AZ-headquartered, operating clinical operations in Colombia. INVIMA approved a clinical trial proposal from BioXcellerator for COVID-19 use of MSCs. The clinic operates an onsite GMP-certified laboratory and has published peer-reviewed safety research on intrathecal MSC delivery.

A market where the letter of the regulation and the practice of the clinics have drifted apart. Not disqualifying, many of the Colombian operators are serious, but the verification burden falls on the patient in a way it doesn't in Mexico or Cayman.

Each operates its own regulatory framework with varying levels of rigor and varying clinical reputations. Patients evaluating these markets should verify the specific regulatory body, the clinic's licensing status, and the operating model with the same diligence applied to any other international destination. We don't have the primary-source depth on these markets to characterize them in detail.

These markets operate under regulatory frameworks roughly comparable to FDA / EMA. Cell therapy access is primarily through clinical trials rather than commercial clinic practice. Useful as contrast points showing that the U.S. is not alone in its regulatory posture, multiple other developed markets have made similar choices.